MARKET

IDRA

IDRA

Idera Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.080
-0.030
-2.70%
Closed 16:00 09/27 EDT
OPEN
1.050
PREV CLOSE
1.110
HIGH
1.110
LOW
1.050
VOLUME
361.50K
TURNOVER
--
52 WEEK HIGH
6.14
52 WEEK LOW
0.9710
MARKET CAP
56.98M
P/E (TTM)
-0.8850
1D
5D
1M
3M
1Y
5Y
Idera Pharmaceuticals Q2 EPS $(0.15) Up From $(0.24) YoY
Idera Pharmaceuticals (NASDAQ:IDRA) reported quarterly losses of $(0.15) per share. This is a 37.5 percent increase over losses of $(0.24) per share from the same period last year.
Benzinga · 08/09 21:44
BioCryst Appoints Vincent Milano to Board of Directors
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors.
GlobeNewswire · 07/28 11:00
Thinking about buying stock in Entera Bio, Torchlight Energy, Idera Pharmaceuticals, Nikola Corp, or Orphazyme?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENTX, TRCH, IDRA, NKLA, and ORPH.
PR Newswire - PRF · 06/23 14:45
44 Biggest Movers From Yesterday
Gainers
Benzinga · 06/23 08:44
Idera Pharmaceuticals up 22% following insider share purchase
Foryou13/iStock via Getty Images Shares of Idera Pharmaceuticals (IDRA) are up 22% in morning trading. An SEC filing after the closing bell yesterday showed that Chief Operating Officer Daniel Soland
Seekingalpha · 06/22 15:41
Idera Pharmaceuticals, Beyond Air leads healthcare gainers; Mereo BioPharma, Portage Biotech among major losers
Gainers: Idera Pharmaceuticals (IDRA) +22%, Beyond Air (XAIR) +14%, Clover Health Investments (CLOV) +14%, Adial Pharmaceuticals (ADIL) +13%, CollPlant Biotechnologies (CLGN) +10%.Losers: Mereo BioPharma (MREO) -9%, Portage Biotech (PRTG) -9%, Petros Pharm...
Seekingalpha · 06/22 15:02
Thinking about buying stock in Biocept, Histogen, Idera Pharmaceuticals, Satsuma Pharmaceuticals, or Clover Health Investments?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, HSTO, IDRA, STSA, and CLOV.
PR Newswire - PRF · 06/22 13:31
Sanderson Farms, GameStop among notable premarket gainers
vTv Therapeutics (VTVT) +28% on licensing agreement with Cantex.Adial Pharmaceuticals (ADIL) +22%.Bio-Path Holdings (BPTH) +22% as USPTO grants a new patent.Beyond Air (XAIR) +12%.Sanderson Farms (SAFM) +12% as it explores a potential sale.Idera
Seekingalpha · 06/22 12:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IDRA. Analyze the recent business situations of Idera Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IDRA stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 86
Institutional Holdings: 8.87M
% Owned: 16.82%
Shares Outstanding: 52.76M
TypeInstitutionsShares
Increased
11
1.60M
New
9
598.30K
Decreased
14
1.30M
Sold Out
18
4.39M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.15%
Pharmaceuticals & Medical Research
-0.90%
Key Executives
Non-Executive Chairman/Independent Director
James Geraghty
President/Chief Executive Officer/Director
Vincent Milano
Chief Financial Officer/Senior Vice President
John Kirby
Chief Operating Officer/Senior Vice President
Daniel Soland
Senior Vice President/General Counsel/Secretary
Bryant Lim
Independent Director
Cristina Csimma
Independent Director
Michael Dougherty
Independent Director
Mark Goldberg
Independent Director
Maxine Gowen
Independent Director
Carol Schafer
No Data
  • All
  • Financials
  • Insiders
More
About IDRA
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.

Webull offers kinds of Idera Pharmaceuticals Inc stock information, including NASDAQ:IDRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDRA stock methods without spending real money on the virtual paper trading platform.